🔗 Share this article

While America proceeds with historic changes to its vaccine guidelines, a particular individual has surfaced somewhat surprisingly: Høeg, a US-based sports medicine doctor and epidemiologist who first made her name by questioning coronavirus vaccinations in the pandemic and has concentrated on alleged deaths following COVID-19 vaccination in her recent tenure at the US Food and Drug Administration (FDA).

Scheduled Shifts to Childhood Immunization Program

Agency leaders had intended to unveil sweeping revisions to the pediatric vaccination calendar earlier this month, aligning the US with Denmark’s national calendar, it is understood – a significant shift that would place the US at odds with a large portion of the world with insufficient data for public health gain. The planned update has been pushed back until the next year.

In place of the top vaccines chief, Høeg is listed to speak at the gathering. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the center this calendar year.

A New Direction at the Agency

The acting appointment might represent a tighter collaboration between the pharmaceutical and vaccine centers as Høeg and Prasad strengthen their influence at the FDA – and it points to a greater focus upon rolling back long-standing immunizations at the FDA.

The new acting director has often pushed for halting certain pediatric shot schedules in the US in order to be more like Denmark, a nation with nationalized medicine and a number of inhabitants about the size of the state of Wisconsin.

To date comments, she has kept her attention on vaccination policy – traditionally the domain of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Concerns Over Expertise

Dr. Høeg has no apparent background in pharmaceutical research, approval processes or leadership, which has been typical for previous heads of the CBER. She has been employed at the FDA as a key advisor to the FDA chief and the vaccine center since spring.

“It seems she lacks to have any of the qualifications” for overseeing the drug-regulation department, remarked Dr. Jonathan Howard. “She has not conducted a clinical trial. She lacks experience in managing a major agency. She has no expertise in pharmaceutical oversight.”

Former commissioners of the center would “grasp legal statutes and the research of medication creation”, commented a former acting FDA commissioner. “Frankly, she lacks the kind of background that previous people who led the center have had.”

The drug center has an immense range of responsibilities at the FDA, she pointed out.

“The public just zeroes in on the innovative therapies, but the generic drug division clears a multitude of off-brand pharmaceuticals. There’s a biologic copycat branch, OTC medication office and other areas, and all of those must be supervised,” Woodcock explained. “The thing you neglect, that is the part that I always told people is going to cause problems.”

Furthermore, a substantial management aspect to the job, which manages in excess of 5,000 personnel. “It is a massive leadership role, if you do it right,” Woodcock concluded.

Official Statement and Controversial Initiatives

In response to inquiries about Høeg’s fitness for the role and whether this appointment signifies greater collaboration among agency officials on immunizations, a spokesperson said that the “questions rely on incorrect assumptions”.

“Her experience matches the functions of her job,” the representative said, citing the period Høeg spent advising the agency head on “drug safety and approval science, including computational safety modeling and vaccine surveillance”.

As the temporary head, Dr. Høeg inherits the commissioner’s controversial expedited review system, a controversial expedited therapy clearance system that reportedly troubled her preceding directors. “By what process are these drugs being selected for this fast-track system? Who makes the decisions?” Howard asked. “There’s a lot of secrecy occurring at the agency right now.”

Broadly speaking, he stated, “the FDA appears to be shifting towards less stringent oversight of most medications, with the exception of shots.”

Documented History on Immunizations

Concerning vaccines, Høeg has a clearer, if troubling, history, critics have noted. She authored a study using non-validated public submissions to determine the rate of myocarditis following Covid vaccination. She consulted for the Florida chief medical officer Joseph Ladapo, who reportedly have altered data to indicate Covid vaccines are riskier than they are.

Included in her “wish list” for the current federal leadership featured revising regulations for new vaccines and halting “non-essential” vaccines, she remarked after the election on a audio program. At the FDA, Høeg has allegedly floated the idea of preventing young men from obtaining Covid vaccinations.

“She is an complete true believer who commences with her conclusions and reverse-engineers to accommodate the science in a very disingenuous, dishonest manner,” Howard said.

Taking Control and a “Revenge Tour”

Dr. Høeg joined fellow dissenters, {like|